MicroPort Scientific (853) H1 2024 earnings summary

Executive summary

• Revenue for the six months ended 30 June 2024 increased by 17.0% year-over-year (excluding FX impact) to US$558.7 million, driven by strong growth across all major business segments and robust overseas expansion.

• Gross profit rose 14.6% to US$330.6 million, while net loss narrowed by 51.5% to US$106.7 million; non-HKFRS adjusted net loss decreased by 63.1% to US$68.4 million.

• Operating expense ratio improved significantly from 94% to 64%, with R&D expense ratio dropping from 39% to 21% due to cost optimization and focus on core businesses.

• Overseas revenue surged 44% year-over-year, now accounting for 45.2% of total revenue, reflecting the success of the global expansion strategy.

• Finance costs rose 30% to US$48.4 million due to higher borrowings and convertible bond interest.

Financial highlights

• Revenue: US$558.7 million (up 17.0% year-over-year, excluding FX impact).

• Gross profit: US$330.6 million (up 14.6%).

• Net loss: US$106.7 million (down 51.5%).

• Non-HKFRS adjusted net loss: US$68.4 million (down 63.1%).

• Cash and cash equivalents: US$740.1 million as of 30 June 2024.

Outlook and guidance

• Focus remains on improving financial health, core business consolidation, domestic and international market expansion.

• Continued cost control, resource focus, and divestiture of non-core businesses planned.

• Emphasis on accelerating R&D and registration of innovative medical devices with strong market potential.

• Management expects continued industry growth but notes short-term macroeconomic and policy uncertainties.